Patents by Inventor Matthew BOOTY

Matthew BOOTY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSE
    Publication number: 20240132839
    Abstract: The present application provides peripheral blood mononuclear cells comprising an antigen, methods of manufacturing such PBMCs, and methods of using such PBMCs, such as for modulating an immune response in an individual. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.
    Type: Application
    Filed: May 16, 2023
    Publication date: April 25, 2024
    Applicant: SQZ Biotechnologies Company
    Inventors: Armon R. SHAREI, Howard BERNSTEIN, Scott LOUGHHEAD, Matthew BOOTY, Katarina BLAGOVIC, Kelan HLAVATY, Defne YARAR, Emrah Ilker OZAY, Carolyne Kelly SMITH
  • Delivery of biomolecules to PBMCs to modify an immune response
    Patent number: 11692168
    Abstract: The present application provides peripheral blood mononuclear cells comprising an antigen, methods of manufacturing such PBMCs, and methods of using such PBMCs, such as for modulating an immune response in an individual. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 4, 2023
    Assignee: SQZ Biotechnologies Company
    Inventors: Armon R. Sharei, Howard Bernstein, Scott Loughhead, Matthew Booty, Katarina Blagovic, Kelan Hlavaty, Defne Yarar, Emrah Ilker Ozay, Carolyne Kelly Smith
  • COMBINATION THERAPY WITH MODIFIED PBMCS AND AN IMMUNOCONJUGATE
    Publication number: 20230181712
    Abstract: The present application provides methods for stimulating an immune response in an individual comprising administering a composition of nucleated cells (e.g., PBMCs) comprising an intracellular exogenous antigen in conjunction with administering an immunoconjugate comprising a variant IL-2 polypeptide and a second polypeptide. The variant IL-2 polypeptide exhibits reduced affinity to the ?-subunit of the IL-2 receptor. The second polypeptide targets a tumor cell or a T cell.
    Type: Application
    Filed: May 10, 2021
    Publication date: June 15, 2023
    Inventors: Pablo UMAÑA, Christian KLEIN, Christine TRUMPFHELLER, Valeria G. NICOLINI, Laura CODARRI DEAK, Scott LOUGHHEAD, Matthew BOOTY
  • FORMULATIONS OF PBMCS
    Publication number: 20220241392
    Abstract: The present application provides formulations of modified peripheral blood mononuclear cells (PBMCs), wherein the formulation comprises: PBMCs comprising at least one antigen (e.g., a human papillomavirus (HPV) antigen) and a cryopreservation medium. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.
    Type: Application
    Filed: December 28, 2021
    Publication date: August 4, 2022
    Inventors: Howard BERNSTEIN, Scott LOUGHHEAD, Matthew BOOTY, Kelan HLAVATY, Tarek ABDELJAWAD, Maisam DADGAR, Jason MURRAY, David CHIRGWIN, Harry AN, Armon R. SHAREI
  • DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSE
    Publication number: 20200318066
    Abstract: The present application provides peripheral blood mononuclear cells comprising an antigen, methods of manufacturing such PBMCs, and methods of using such PBMCs, such as for modulating an immune response in an individual. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.
    Type: Application
    Filed: February 27, 2020
    Publication date: October 8, 2020
    Inventors: Armon R. SHAREI, Howard BERNSTEIN, Scott LOUGHHEAD, Matthew BOOTY, Katarina BLAGOVIC, Kelan HLAVATY, Defne YARAR, Emrah Ilker OZAY, Carolyne Kelly SMITH